Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.92 USD
Change Today -0.18 / -4.39%
Volume 22.7K
BONE On Other Exchanges
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

bacterin international holdi (BONE) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/6/14 - $8.10
52 Week Low
11/20/14 - $2.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bacterin international holdi (BONE) Related Businessweek News

No Related Businessweek News Found

bacterin international holdi (BONE) Details

Bacterin International Holdings, Inc. develops, manufactures, and markets biologics products in the United States and internationally. The company offers products that are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, neurosurgery, and regeneration in knee and other joint surgeries. Its products include OsteoSponge, which provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler; OsteoSelect DBM putty, an osteoinductive product used by surgeons as a bone void filler in the extremities and pelvis; and OsteoWrap that wraps around non-union fractures to assist with fusion, and could be used in conjunction with a hardware plate system. The company also provides OsteoLock and BacFast HD facet stabilization dowels that are used to augment spinal procedures; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and hMatrix dermal scaffold, which promotes cellular ingrowth, tissue vascularization, and regeneration. In addition, it processes and sells sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company’s products include 3Demin cortical fibers, 3Demin boats, and 3Demin strips made from cortical bone and primarily used in spine procedures. It markets its products through direct sales, as well as through distributor relationships. Bacterin International Holdings, Inc. is headquartered in Belgrade, Montana.

148 Employees
Last Reported Date: 03/18/15

bacterin international holdi (BONE) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $500.2K
Total Annual Compensation: $153.8K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $350.0K
Chief Operating Officer
Total Annual Compensation: $338.6K
Chief Scientific Officer
Total Annual Compensation: $271.1K
Compensation as of Fiscal Year 2014.

bacterin international holdi (BONE) Key Developments

NYSE MKT Files Form 25 To Remove Bacterin International Holdings Common Stock From Listing

On May 6, 2015, the NYSE MKT filed a Form 25 with the Securities and Exchange Commission to remove Bacterin International Holdings, Inc.’s common stock from listing on the NYSE MKT. This will not have any effect on trading of common stock since the company previously transitioned trading of common stock on April 9, 2015 to the OTCQX marketplace under the ticker symbol "Bone".

Bacterin International Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for 2015

Bacterin International Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. First quarter 2015 revenue was approximately $9.5 million, an increase of 6.6% compared to approximately $8.9 million for the same period during 2014. Sequentially, first quarter 2015 revenue increased 4.6% over fourth quarter 2014 revenue of $9.1 million. The reported first quarter 2015 revenue represents a new record and the sixth consecutive quarter of increased year-over-year revenue growth since Dan Goldberger joined Bacterin as Chief Executive Officer in August 2013. The first quarter 2015 loss from operations was approximately $1.7 million, compared to approximately $1.2 million in the first quarter of 2014. The increased loss primarily reflect the Company's ongoing execution of its strategy to increase and enhance field sales assets to drive future revenue growth as well as the Company's expanded product development initiatives. The reported first quarter 2015 net loss of $4.2 million is essentially flat when compared to $4.1 million for the same period during 2014. EBITDA for the first quarter of 2015 was a loss of $1.3 million compared to a loss of $0.7 million for the same period during 2014 and $1.1 million for the fourth quarter of 2014. The company incurred approximately $302,000 of expenses in the first quarter that will be eliminated over the second half of 2015. Excluding this figure, the EBITDA loss for the first quarter of 2015 would have been approximately $966,000. Loss from operations before impairment was $1.7 million against $1.2 million a year ago. Net loss from operations before benefit for income taxes was $4.2 million against $4.1 million a year ago. Net cash used in operating activities was $2.1 million against $2.2 million a year ago. Purchases of property and equipment and intangible assets were $48,768 against $54,933 a year ago. For the full year 2015, the company reaffirmed its revenue guidance of approximately $40 million to $42 million, which compares to $35.3 million reported for 2014.

Bacterin International Holdings, Inc. to Report Q1, 2015 Results on May 05, 2015

Bacterin International Holdings, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BONE:US $3.92 USD -0.18

BONE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $1.67 USD -0.03
Cardica Inc $0.40 USD -0.0101
Cogentix Medical Inc $1.67 USD 0.00
Cytori Therapeutics Inc $0.68 USD +0.0189
Stereotaxis Inc $1.79 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation BONE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACTERIN INTERNATIONAL HOLDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at